Neuropsychiatric Disorders in Pediatric Long COVID-19: A Case Series - Moleculera Labs

Prescriber Portal Login

Neuropsychiatric Disorders in Pediatric Long COVID-19: A Case Series

According to the authors, this is the first study to report movement disorders in COVID-19 long haulers.

This was a case series of 5 pediatric patients with psychiatric and neurological symptoms associated with long COVID-19. ² All patients, mainly males, reported asymptomatic-to-mild COVID-19.

“The subsequent occurrence of neuropsychiatric complications was noticed at different points of time,” the authors found, “Interestingly, in older patients, psychiatric symptoms arose during the acute phase of infection, while in younger patients they occurred after weeks or months.”

“The most recurrent symptoms reported were abnormal movements, anxiety, and emotional dysregulation. Unusually, involuntary movements were frequently reported in three out of five patients, especially in the younger ones.”

The authors stated that, “Several theories have been formulated to explain the correlation between COVID-19 infection and the occurrence of psychiatric/neurologic disorders during both the acute and post-acute phase, including direct brain infection, neuroinflammation, autoimmunity, and response to pandemic-related stress.”

Learn More About Testing SCHEDULE CONSULTATION

REFERENCES

Guido CA, Lucidi F, Midulla F, Zicari AM, Bove E, Avenoso F, Amedeo I, Mancino E, Nenna R, De Castro G, Capponi M, Cinicola BL, Brindisi G, Grisoni F, Murciano M, Spalice A; Long-Covid Group of Department of Maternal Sciences. Neurological and psychological effects of long COVID in a young population: A cross-sectional study. Front Neurol. 2022 Aug 17;13:925144. doi: 10.3389/fneur.2022.925144. PMID: 36062008; PMCID: PMC9428748.
Savino R, Polito AN, Arcidiacono G, Poliseno M, Lo Caputo S. Neuropsychiatric Disorders in Pediatric Long COVID-19: A Case Series. Brain Sci. 2022 Apr 19;12(5):514. doi: 10.3390/brainsci12050514. PMID: 35624901; PMCID: PMC9138973.
Owji M, Naser Moghadasi A, Gholamian F, Mousavi SY. Obsessive compulsive disorder as a presenting symptom of COVID-19: A case-series from Iran. Caspian J Intern Med. 2022;13(Suppl 3):259-263. doi: 10.22088/cjim.13.0.259. PMID: 35872671; PMCID: PMC9272957.

B. Robert Mozayeni, MD

Medical and Clinical Advisor

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor

Medical Database, Inc., President and CEO

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.

Rodney Cotton, MBA

Moleculera Labs Board Member

Rodney Cotton, MBA is an entrepreneurial thought leader in the pharmaceutical/biotech industry who is known for his holistic perspective, bias for action in the face of challenges, and commitment to agile processes.

Rod is an independent director for Orchard Software, a private equity-backed health technology company owned by Francisco Partners; an advisory board member to Flo2 Ventures, a venture capital-backed healthcare and health equity accelerator; and a member of the board of directors and three board committees (Audit, Compliance & Finance; Governance & Equity; and Quality of Care) for Community Health Network.

He built a successful career at Roche spanning more than two decades and culminating in the role of SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO for Roche Diagnostics, the North American headquarters of the world’s largest ($17B) diagnostics company.

While at Roche, Rod led key enterprise initiatives, such as milestone corporate communications, health equity coalitions, the US/Roche Group audit, and global/US acquisition integrations. With 40+ years of experience, he drove the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 total reports, managed P&L of more than $1 billion, and served as a key member of the senior leadership team executing the most significant restructuring of the company in two decades.

In the face of the COVID-19 pandemic, Rod and his team at Roche accelerated six ground breaking products in 11 months, including the first launch of the market’s most accurate and in demand molecular diagnostic test. He also solved extraordinary challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self manufacturing in line with testing guidelines.

A frequent public speaker on health equity and other topics, Rod was named one of the Most Influential Black Executives in Corporate America by Savoy Magazine and one of the Top Blacks in Healthcare by BlackDoctor.org. He also received The Sagamore of the Wabash Award, one of the highest Indiana State honors, bestowed by Indiana Governor Eric J. Holcomb.

Rod holds an M.B.A. from California State University, Dominguez Hills, an M.S. in Strategic Management from the University of Southern California, and a B.A. in Biological Sciences & Technology from the University of California at Santa Barbara.